Market failure and the poverty of new drugs in maternal health
about
Pharmaceutical laws and regulations in Iran: An overviewEbola research funding: a systematic analysis, 1997-2015Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013Drug development for maternal health cannot be left to the whims of the marketThe Grand Convergence: Closing the Divide between Public Health Funding and Global Health NeedsNew medicines for tropical diseases in pregnancy: catch-22.Folic acid supplementation and spontaneous preterm birth: adding grist to the mill?Treating the dysfunctional placenta.In vitro assessment of mouse fetal abdominal aortic vascular function.Drugs in pregnancy: Implications for a cardiologist.Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype.We don't know what we don't study: the case for research on medication effects in pregnancyPreeclampsia - will orphan drug status facilitate innovative biological therapies?Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor.Investments in sexually transmitted infection research, 1997-2013: a systematic analysis of funding awarded to UK institutionsImproving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy.Tumor-homing peptides as tools for targeted delivery of payloads to the placenta.Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template.The grand challenges in obstetric and pediatric pharmacology.New therapeutic targets for amyotrophic lateral sclerosis.Oxytocin: its mechanism of action and receptor signalling in the myometrium.The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy.Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transport.Placental Homing Peptide-microRNA Inhibitor Conjugates for Targeted Enhancement of Intrinsic Placental Growth Signaling.The challenges of licensing drugs for use in pregnancy.Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy.Relative and absolute addressability of global disease burden in maternal and perinatal health by investment in R&D.Drug development in preeclampsia: a 'no go' area?Drug development and obstetrics: where are we right now?The perils of protection: vulnerability and women in clinical research.Dietary interventions for fetal growth restriction - therapeutic potential of dietary nitrate supplementation in pregnancy.Community, constituency, and morbidity: applying Chervenak and McCullough's criteria.Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice.Moving Forward With Research Involving Pregnant Women: A Critical Role for Wisdom From the FieldDrug development for use during pregnancy: impact of the placentaMelatonin Increases Fetal Weight in Wild-Type Mice but Not in Mouse Models of Fetal Growth Restriction
P2860
Q26741873-5CC3A4D4-DC59-4C72-BFF6-37F15EE75289Q28119506-74E68394-F965-419E-A4E6-79CEEBA524FBQ28385805-943B6B3B-6851-46B3-8E78-D285FBF4B716Q28473418-8999EB2C-6BAA-454E-8AB1-836954AFBBCAQ30385572-504B8D16-38EF-44AE-8B1A-14E2DEA5F3CAQ33344906-A90F8968-BB86-4832-9C44-12EB58A7B89CQ33443882-4F975884-B738-4143-9B44-3AA449B9F063Q33917113-646DDAFE-1D72-45A9-B9D9-FD50C43A37D0Q34201168-DD0175EC-8F8B-4B37-8DFC-19AAB6B4C6E7Q34467069-3ED859D5-238F-4037-8634-12D991DE8DECQ35035567-D6C38551-C51D-4E96-B17C-AE9FFA9909B1Q35119048-34C3F078-64DC-4E25-9CFA-A38C0989C3B0Q35124440-30D9DF1F-C47F-4810-B9ED-EFABFC9A5520Q35570951-2191AE3C-EF90-43D1-A63A-458C9B3AC77DQ35980127-592B7FF2-DBFF-4DAE-85FC-CB176960590CQ36179253-224652E1-24EA-4ED8-99D8-599B332A1024Q37056248-94D20933-5054-400A-97BC-2660B1AEFF29Q37081139-348D9B00-99B0-48A8-A4C8-9E50B0C30208Q37417869-3BC0BF84-5B87-4777-9F93-07554CFF717CQ37816447-6C6A44AA-969E-4606-8049-59C403C00D92Q38216874-12956E28-BB06-471E-8FC8-02206F193814Q38853715-9117DF86-E366-49DD-8436-9C455765996CQ39210009-BBD11C1D-24C6-4746-8B3F-6ADD12ECDE55Q41455540-B0BA7883-6979-4FD0-94B5-59A8F27E34F8Q44793633-81CBD3AF-D047-48BE-9315-0A2000A20853Q44802112-96EEBED5-40D5-41C1-9649-7688591DE7AFQ46328009-3B2D0FDF-F190-4FF5-AE51-D3B9692A473EQ46328251-E1E8E48E-58F7-494E-BA94-A66BFB458308Q47587613-0570BD29-9579-4150-9ADF-3ADD7BFA75A5Q48240764-A4FF14CD-5586-42A1-8BD2-28966EC701F7Q48351024-D33F7ACD-318C-485A-AD0C-14DCD0D38262Q48681622-169CC344-5339-406B-9E21-B7600D1D5097Q55354236-A96B4317-B289-4363-B1C3-9563C16E3E7EQ58278158-6CC7B059-A91D-4CAF-BAA9-401F6605688AQ58392274-3F096BEF-CA45-4041-8B02-4FA3CDAB06D7Q58777315-B6794B6B-F774-4080-9E2D-EDB91C22ADB2
P2860
Market failure and the poverty of new drugs in maternal health
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Market failure and the poverty of new drugs in maternal health
@ast
Market failure and the poverty of new drugs in maternal health
@en
Market failure and the poverty of new drugs in maternal health.
@nl
type
label
Market failure and the poverty of new drugs in maternal health
@ast
Market failure and the poverty of new drugs in maternal health
@en
Market failure and the poverty of new drugs in maternal health.
@nl
prefLabel
Market failure and the poverty of new drugs in maternal health
@ast
Market failure and the poverty of new drugs in maternal health
@en
Market failure and the poverty of new drugs in maternal health.
@nl
P2860
P1433
P1476
Market failure and the poverty of new drugs in maternal health
@en
P2860
P356
10.1371/JOURNAL.PMED.0050022
P407
P577
2008-01-01T00:00:00Z